Navigation Links
ECOG in Medical News

Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations

...miting, nausea, diarrhea, anorexia and abdominal pain.(7) Updated efficacy and safety data from this study demonstrated that patients with an ecog performance status of 0-1 had a median overall survival of 264 days (n=56).(7) These data suggest that BIBF 1120 has single-agent activity in patients...

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

... Patient Demographics : The treatment arms were well-balanced for patient demographics and key ovarian cancer disease characteristics, including age, ecog Performance Status, presence of bulky disease and history of prior taxane therapy. A greater number of patients (13, 20%) had platinum refractory dis...

Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients

...trial are important, because they will likely change practice and improve the outcome for many patients with AML," Dr. Martin Tallman, chairman of the ecog leukemia committee and a professor of medicine at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Cen...

New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer

...alysis of Effect of Macroscopic Vascular Invasion, Extrahepatic Spread, and ecog Performance Status on Outcome Yoon-Koo Kang - ASAN Medical Center, So...ofile consistent with the overall study population, independent of baseline ecog performance status and the presence or absence of macroscopic vascular inva...

New 'everyday cognition' scale tracks how older adults function in daily life

...r time a "must" for progressive disorders. The ecog was shown to be valid in several ways. First, its ...Mild Cognitive Impairment (MCI), and dementia, the ecog was sensitive to the early functional changes present in MCI. Thus, the authors believe, the ecog shows great promise as a useful screening measure ...

Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

...l arm respectively. The demographics of the patients in the treatment arm were essentially similar to patients in the control arm across age, sex, and ecog performance status. Mr. Kessman added, "Now that the clinical hold has been lifted by the FDA, we have the opportunity to move forward in first rela...

Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results

...w CTI's Marketing Authorization Application (MAA) for OPAXIO for first-line treatment of patients with non-small cell lung cancer (NSCLC) with ecog (Eastern Cooperative Oncology Group) performance status 2 (PS2) o Announced completion of enrollment in the phase III EXTEND (PIX301) clini...

Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium

.... "We believe the consistent results seen in both the Kaiser Permanente and ecog studies indicate that quantitative RT-PCR is a reliable method for determin... status. -- Abstract #87 Poster presentation: ER and PR Assessment in ecog 2197; Comparison of Locally Determined IHC with Centrally Determined IH...

New Clinical Trial Results Could Improve Survival for Myeloma Patients

...ve Oncology Group (ECOG). Based on these findings, ecog has suspended further patient enrollment for this ...patients with myeloma. Preliminary analysis of the ecog data shows patients taking REVLIMID plus low dose ...ful to all of the patients who participated and to ecog Group chair, Dr. Robert Comis and Myeloma Committe...

A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer

...peated the treatment at 6 months and 12 months after the initial treatment. Among these patients, 50% had a marked decrease in pain and improvement in ecog performance status, according to specialists. In 8 cycles, due to the response to treatment, the dose of vinorelbine was reduced 50% and in 4 cycles i...

More>>

ECOG in Medical Technology

Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients

...lood disorders; 43 percent in patients with adverse cytogenetics; 40 percent in patients 70 years of age and older; and 38 percent in patients with an ecog performance status of 2. Remission rates in patients with up to three pre-defined risk factors required for study enrollment also exceeded 40 percent....

Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

...ents with untreated de novo AML who are age 60 or older and have at least one of the following adverse prognostic factors: age greater or equal to 70, ecog performance status equal to 2, unfavorable cytogenetics or organ dysfunction. The primary endpoint of the trial is the overall complete response rate ...

European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review

...on Application (MAA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) with ecog (Eastern Cooperative Oncology Group) performance status 2 (PS2). CTI submitted the MAA at the beginning of March. The validation of the MAA for XYOTAX...

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)

...es Agency (EMEA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) who have ecog (Eastern Cooperative Oncology Group) performance status 2 (PS2). The application is based on a positive opinion CTI received from the EMEA's Scientifi...

Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

...ial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ecog performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthrac...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

...pt and convenient access to REVLIMID through contracted pharmacies. About ecog The Eastern Cooperative Oncology Group (ECOG) was established in 1955 as ...bers of the group. Funded primarily by the National Cancer Institute (NCI), ecog has evolved from a five member consortium of institutions on the East Coast...

The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients

...ve Oncology Group (ECOG). Based on these findings, ecog has suspended further patient enrollment for this ...patients with myeloma. Preliminary analysis of the ecog data shows patients taking REVLIMID plus low dose ...ful to all of the patients who participated and to ecog Group chair, Dr. Robert Comis and Myeloma Committe...

Low-Dose Steroid Combined With Lenalidomide Prolongs Survival Compared With High-Dose Steroid for Multiple Myeloma Treatment

...ry and as an immunosuppressant and has numerous uses in medical practice. ecog has a long history in developing new treatments for multiple myeloma, according to Robert L. Comis, M.D., ecog group chairperson. The application of this effective and less toxic approac...

Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting

...ed for known prognostic factors including baseline ecog status, tumor type, tumor stage, baseline FACT-F c...y therapy versus all other eligible patients), and ecog status (0-1, 2). Demographics were broadly simil...ts had disease stage III or IV (82 percent) and an ecog status of 0 or 1 (72 percent); and baseline Hb was...

Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP Phase II Trial

...herapy, Adequate major organ function ecog PS (performance score) 0-1. Age 18-75... Median 63.11 62.30 62.67 ecog Status 0 16 19 45 ...
ECOG in Medical Dictionary

Electronystagmography

...... Search this site Page last modified: November 4, 2004. OVERVIEW. ENG TEST ( electronystagmography ) ROTATIONAL CHAIR TEST. VEMP testing (link) ecog testing (link) ... Electronystagmography records involuntary eye movements. ... Electronystagmography is performed to evaluate the acoustic...
ECOG in Biological Technology

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

...Nexavar data highlights include: Hepatocellular Carcinoma Effect of Macroscopic Vascular Invasion, Extrahepatic Spread, and ecog Performance Status on Outcome in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: Analysis of Two Phase 3, Randomized Double-Bl...

Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009

...authorization application (MAA) to the European Medicines Agency for OPAXIO for first-line treatment of patients with non- small cell lung cancer with ecog (Eastern Cooperative Oncology Group) performance status 2 (PS2). OPAXIO is a drug candidate which is exclusively partnered with Novartis. Redu...

Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program

...not reach statistical significance, although exploratory analysis yielded promising results in specific patient populations including in patients with ecog performance status of 0 or 1. In April 2008, Lorus' subsidiary GeneSense Technologies entered into an exclusive multinational license agreement for ...

Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting

..., June 3, 2008, 11 - 11:15 a.m., S406 -- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ecog performance status: a subanalysis from the SHARP trial -- Jean-Luc Raoul, MD, PhD, Centre Eugene Marquis, Rennes, France -- Poster 38B, Ab...

European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug

...zation Application (MAA) for OPAXIO (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) with ecog (Eastern Cooperative Oncology Group) performance status 2 (PS2). The EMEA's review process generally takes 15 to 18 months; if the MAA is approved by ...

Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer

...MUC1, a protein antigen that is widely expressed on common cancers including lung, breast and colorectal. About the Phase II Trial 171 patients with ecog 0-2 stage IIIB/IV NSCLC with stable or responding disease after any first-line chemotherapy with or without radiotherapy were randomized to receive St...

Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

...ial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ecog performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthrac...

More>>

Other Tags
(Date:11/24/2014)... 24, 2014 Abington Health ... has joined The Neurology Group and has been ... Center. , A graduate of Vinnica Medical University ... Albert Einstein Medical Center in Philadelphia and completed a ... Sclerosis Center at Weill Cornell Medical College. Ternopolska is ...
(Date:11/24/2014)... The Holiday Inn Westbury - Long ... Children's Association to donate various items consisting of ... other such items.The Association's program is aimed toward helping ... in nursing homes, assisted living facilities and nursing homes. ... being of seniors throughout the Long Island area. The ...
(Date:11/24/2014)... Longmont, CO, and Philadelphia, PA (PRWEB) November 24, ... a provider of care coordination and disease management ... organizations, has chosen to implement Essette’s Medical Management ... powerful new Essette SaaS platform in a program ... latest Essette suite includes Population Health Management, Care ...
(Date:11/23/2014)... (PRWEB) November 24, 2014 iFitDress.com, a well-known ... long black evening gowns . They are now offered ... special offer will last from now to Dec. 15. The ... market. , All the company’s high quality items are ideal ... spending a large sum of money. All its new mint ...
(Date:11/23/2014)... New York, NY (PRWEB) November 23, 2014 ... ) that allege heart attacks, strokes, deep vein ... been filed in a federal multidistrict litigation (MDL) ... Liebhard LLP reports. , Court documents updated ... on Multidistrict Litigation (JPML) show the filing of ...
Breaking Medicine News(10 mins):Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
(Date:11/18/2014)... 2014   News Highlights: ... develop The Partners Data Lake, an agile data ... Lake will allow researcher and clinicians to explore ... the lives of patients , The Partners ... across the Partners system, breaking down physical barriers ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
Other Contents